Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01163253 · ClinicalTrials.gov registry record · Phase 3
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3 study, sponsored by Pfizer.
- Terminated
- Registry status
- Phase 3
- Development phase
- 2,867
- Enrollment target
NCT01163253 is a Phase 3 study that was terminated before completion, run by Pfizer. The registered enrollment target is 2,867 participants.
The verdict
NCT01163253, a Phase 3 study, was terminated before completion, sponsored by Pfizer.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 2,867 participants
- Enrollment target
Study Summary
The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry criteria is met.
Interventions
- DRUG CP-690,550
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,867 participants |
| Start Date | 2010-09 |
| Est. Completion | 2016-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01163253
The ClinicalTrials.gov registry entry for NCT01163253 describes a study currently listed as terminated, categorized as Phase 3. The registered enrollment target is 2,867 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pfizer, which has 1,845 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CP-690,550 is the first listed.
NCT01163253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01163253 about?
NCT01163253 is a clinical study titled "A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis". The main objective of this study is to evaluate the long-term safety of CP-690,550 in patients being treated for moderate to severe chronic plaque psoriasis. This is an open label extension study available to patients who participated in one of the qualifying studies with CP-690,550 providing entry ...
What is the current status of trial NCT01163253?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 2,867 participants. The study started on 2010-09. Estimated completion is 2016-06.
What interventions are being tested in trial NCT01163253?
The interventions under investigation include: CP-690,550 (DRUG).
Who is sponsoring clinical trial NCT01163253?
This trial is sponsored by Pfizer, which has 1,845 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.